Literature DB >> 21412200

The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome.

Dien Dang1, David Cunnington, John Swieca.   

Abstract

INTRODUCTION: The Restless Legs Syndrome is a common sensorimotor disorder, typically amenable to treatment with dopamine agonist therapy. Dopamine agonists have been associated with emergent impulse control disorders (ICDs) when used in patients with Parkinson disease, and ICDs have now been reported in individuals with RLS on dopamine agonist therapy. Our aim was to characterize cases of emergent ICDs in Australian patients with focus on the dopamine agonists implicated and the social significance of ICDs.
METHOD: A series of RLS patients on dopamine agonist therapy were identified with ICDs over a 2-year period. Additional cases of ICDs were found using a mailout questionnaire designed to capture those with high impulsivity. These patients were assessed using the Barratt Impulsiveness Scale, Version 11, and a modified Minnesota Impulse Disorders Interview. Case records and medication schedules were evaluated.
RESULTS: Twelve cases of patients with de novo ICDs were found with a range of impulsive behaviors including pathological gambling, kleptomania, compulsive shopping, and hypersexuality. Criminality, suicidality, and marital discord also were featured. These occurred over a wide range of latencies and l-dopa exposures. DISCUSSION: This group of Australian RLS patients with ICDs display high levels of impulsivity and is the first to use the BIS-11 questionnaire in this setting. Impulse control disorders can occur over a wide range of dopamine agonist therapy types and dose exposures. Impulse control disorder tendencies may persist, despite withdrawal of dopamine agonists. The emergence of ICDs needs careful consideration in light of their potentially devastating financial, social, and marital consequences.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21412200     DOI: 10.1097/WNF.0b013e31820d6699

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  15 in total

1.  Increased Risk for New-Onset Psychiatric Adverse Events in Patients With Newly Diagnosed Primary Restless Legs Syndrome Who Initiate Treatment With Dopamine Agonists: A Large-Scale Retrospective Claims Matched-Cohort Analysis.

Authors:  Cheryl Hankin; Daniel Lee; Diego Garcia-Borreguero; Zhaohui Wang
Journal:  J Clin Sleep Med       Date:  2019-09-15       Impact factor: 4.062

2.  'You never told me I would turn into a gambler': a first person account of dopamine agonist--induced gambling addiction in a patient with restless legs syndrome.

Authors:  Henrietta Bowden Jones; Sanju George
Journal:  BMJ Case Rep       Date:  2011-08-24

3.  Part 2: Introduction to the Pharmacotherapy of Parkinson's Disease, With a Focus on the Use of Dopaminergic Agents.

Authors:  George DeMaagd; Ashok Philip
Journal:  P T       Date:  2015-09

4.  Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study.

Authors:  Maya Barake; A Eden Evins; Luke Stoeckel; Gladys N Pachas; Lisa B Nachtigall; Karen K Miller; Beverly M K Biller; Nicholas A Tritos; Anne Klibanski
Journal:  Pituitary       Date:  2014-04       Impact factor: 4.107

5.  Uncertainty about mapping future actions into rewards may underlie performance on multiple measures of impulsivity in behavioral addiction: evidence from Parkinson's disease.

Authors:  Bruno B Averbeck; Atbin Djamshidian; Sean S O'Sullivan; Charlotte R Housden; Jonathan P Roiser; Andrew J Lees
Journal:  Behav Neurosci       Date:  2013-04       Impact factor: 1.912

6.  Decision-making, reward-seeking behaviors and dopamine agonist therapy in restless legs syndrome.

Authors:  Sophie Bayard; Muriel Croisier Langenier; Yves Dauvilliers
Journal:  Sleep       Date:  2013-10-01       Impact factor: 5.849

7.  Receptor-specific modulation of risk-based decision making by nucleus accumbens dopamine.

Authors:  Colin M Stopper; Shahin Khayambashi; Stan B Floresco
Journal:  Neuropsychopharmacology       Date:  2012-11-29       Impact factor: 7.853

8.  Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study.

Authors:  Irina Bancos; Michael R Nannenga; J Michael Bostwick; Michael H Silber; Dana Erickson; Todd B Nippoldt
Journal:  Clin Endocrinol (Oxf)       Date:  2013-12-16       Impact factor: 3.478

9.  Dopamine and Gambling Disorder: Prospects for Personalized Treatment.

Authors:  Andrew Kayser
Journal:  Curr Addict Rep       Date:  2019-03-07

10.  Sleep disturbances and suicidality: a common association to look for in clinical practise and preventive care.

Authors:  Christine Norra; Nadja Richter; Georg Juckel
Journal:  EPMA J       Date:  2011-07-23       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.